KKR has acquired a majority stake in HealthCare Royalty Partners, pushing the investment firm further into the healthcare ...

NEW YORK, Aug. 4, 2025 /PRNewswire/ -- OrbiMed, a leading global healthcare investment firm, today announced it has raised $1.86 billion in commitments for OrbiMed Royalty and Credit Opportunities ...

Investment firm KKR (NYSE:KKR) announced on Wednesday the acquisition of a majority stake in biopharma royalty acquisition company, HealthCare Royalty Partners. The acquisition marks KKR's expansion ...

KKR & Co. Inc., a leading global investment firm, today announced that it has acquired a majority ownership stake in HealthCare Royalty Partners (HCRx), a leading biopharma royalty acquisition company ...

KKR executives said strong momentum in their business gave them confidence on Thursday of beating earnings targets for 2026, ...

Under the terms of the agreement, Ardelyx will receive from HealthCare Royalty a $10 million upfront payment, an additional $5 million following Kyowa Kirin's receipt of regulatory approval to ...

HealthCare Royalty Partners (“HCR") is a private investment firm that purchases royalties and uses debt-like structures to invest in commercial or near-commercial stage biopharmaceutical assets.

MacroGenics received $70 million upfront cash payment from Sagard Healthcare Partners (Sagard) MacroGenics’ cash runway extended through first half of 2027 ROCKVILLE, MD, June 10, 2025 (GLOBE ...

About HealthCare Royalty Partners HCR is a private investment firm that purchases royalties and uses debt-like structures to invest in commercial or near-commercial stage life science assets.

Entering text into the input field will update the search result below ...

ANNOUNCES $230 MILLION ROYALTY MONETIZATION WITH HEALTHCARE ROYALTY PARTNERS * AGENUS INC - TRANSACTION IS COMPRISED OF $190 MILLION OF CASH PROCEEDS AT CLOSING PLUS UP TO $40 MILLION IN MILESTONE ...

Under the terms of the royalty purchase agreement, MacroGenics received a $70 million upfront payment for the sale of its royalty rights on global net sales of ZYNYZ. Following Sagard’s receipt ...